Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

KPV vs VIP: Peptide Comparison

The table below compares structural features, receptor mechanisms, tissue selectivity, and research applications for KPV and VIP peptides. Amino Acid Length 3 amino acids (tripeptide) 28 amino acids (neuropeptide) KPV is 9× smaller. Greater stability, lower im

This comparison does not assign a generated winner or score.

  • The table below compares structural features, receptor mechanisms, tissue selectivity, and research applications for KPV and VIP peptides.
  • Amino Acid Length
  • 3 amino acids (tripeptide)
  • 28 amino acids (neuropeptide)
  • KPV is 9× smaller. Greater stability, lower immunogenicity
  • Molecular Weight
  • ~357 Da
  • ~3,326 Da
  • Size difference drives pharmacokinetics and delivery route
  • Receptor Target
  • Receptor-independent (intracellular)
  • VPAC1/VPAC2 GPCRs
  • KPV bypasses receptor desensitization; VIP allows dose titration
  • Primary Mechanism
  • Inhibits NF-kappaB translocation
  • Elevates cAMP via Gs-protein activation
  • Both suppress NF-kappaB but through independent pathways
  • Plasma Half-Life
  • Minutes (mucosal persistence longer)
  • Seconds to minutes (rapid DPP-IV cleavage)
  • VIP requires modified analogs for systemic use; KPV stable in mucosa
  • Tissue Selectivity
  • Mucosal surfaces, mast cells, gut epithelium
  • Systemic (immune, pulmonary, GI smooth muscle, CNS)
  • KPV = localized; VIP = systemic
  • Immune Modulation
  • Mast cell stabilization, innate immune suppression
  • Th1/Th17 suppression, Treg promotion
  • KPV = innate; VIP = adaptive
  • Administration Route (Preclinical)
  • Oral, topical, intranasal
  • Intraperitoneal, intravenous, subcutaneous
  • KPV functional via mucosal routes; VIP requires parenteral dosing
  • Primary Research Applications
  • IBD, allergic dermatitis, mast cell disorders
  • Autoimmune disease, pulmonary inflammation, neuroprotection
  • Match peptide to immune compartment targeted
  • Purity Requirement
  • >98% for consistent NF-kappaB inhibition
  • >98% (C-terminal amidation critical)
  • Both require high purity. Truncated sequences lose activity
More references

Related material